DAM
APLS

DLD Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

DLD Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-29,300
Closed -$778K – 71
2020
Q1 		$778K Sell
29,300
-40,700
-58% -$1.44M 0.05% 72
2019
Q4 		$2.14M Buy
+70,000
New +$1.94M 0.12% 55

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

DLD Asset Management's APLS Position: Q1 2020 in Review

DLD Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2020, closing a stake of 66,800 shares — an estimated $2.37M sold.

DLD Asset Management first reported a position in APLS in Q4 2019 and held it in 1 quarter. The position peaked at $2.04M in Q4 2019. 143 funds tracked by Wall St. Rank hold APLS as of Q1 2020.

  • DLD Asset Management reported no remaining Apellis Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • DLD Asset Management sold 66,800 Apellis Pharmaceuticals shares in Q1 2020, an estimated $2.37M.
  • DLD Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • DLD Asset Management's Apellis Pharmaceuticals position peaked at $2.04M in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2020.

Based on DLD Asset Management's 13F filing for Q1 2020, filed 14 May 2020.